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Abstract
Background: Granulocytes generally exert protective roles in the central nervous system (CNS), but recent studies
suggest that they can be detrimental in experimental autoimmune encephalomyelitis (EAE), the most common
model of multiple sclerosis. While the cytokines and adhesion molecules involved in granulocyte adhesion to the
brain vasculature have started to be elucidated, the required chemokines remain undetermined.
Methods: CXCR2 ligand expression was examined in the CNS of mice suffering from EAE or exposed to bacterial
toxins by quantitative RT-PCR and in situ hybridization. CXCL1 expression was analyzed in IL-6-treated endothelial
cell cultures by quantitative RT-PCR and ELISA. Granulocytes were counted in the brain vasculature after treatment
with a neutralizing anti-CXCL1 antibody using stereological techniques.
Results: CXCL1 was the most highly expressed ligand of the granulocyte receptor CXCR2 in the CNS of mice
subjected to EAE or infused with lipopolysaccharide (LPS) or pertussis toxin (PTX), the latter being commonly used
to induce EAE. IL-6 upregulated CXCL1 expression in brain endothelial cells by acting transcriptionally and
mediated the stimulatory effect of PTX on CXCL1 expression. The anti-CXCL1 antibody reduced granulocyte
adhesion to brain capillaries in the three conditions under study. Importantly, it attenuated EAE severity when
given daily for a week during the effector phase of the disease.
Conclusions: This study identifies CXCL1 not only as a key regulator of granulocyte recruitment into the CNS, but
also as a new potential target for the treatment of neuroinflammatory diseases such as multiple sclerosis.
Keywords: Neuroinflammation, Neuroimmunity, Chemotaxis, Myeloid cells, Polymorphonuclear cells, Neutrophils,
Cerebral endothelium, Autoimmunity.
Background
Myelin-reactive CD4
+ T lymphocytes play a critical role
in the pathogenesis of multiple sclerosis and its animal
model, EAE [1]. A basic principle in immunology states
that these cells do not act alone, but rather in concert
with different populations of myeloid phagocytes, which
activate them by presenting antigens and producing
proinflammatory molecules, and which execute effector
functions. The phagocytes best known to be involved in
EAE are monocyte-derived CD11c
+ dendritic cells [2-5]
and Ly6C
+ macrophages originating from either
microglia or monocytes [2,4,6,7]. In addition, mounting
evidence suggests the involvement of a third population
of phagocytes, namely granulocytes. Indeed, it has been
reported that granulocytes massively infiltrate the CNS
of EAE mice [8-17], and that EAE is markedly attenu-
ated in mice either treated with antibodies against the
granulocyte proteins CXCR2 and Ly6G, treated with a
small molecule antagonist of CXCR2, or genetically
manipulated to suppress CXCR2 [12,18-20]. Therefore,
granulocytes and the extracellular signaling pathways
that control them represent novel potential therapeutic
targets for multiple sclerosis.
We have uncovered a population of rod-shaped granu-
locytes that patrol the CNS vasculature by crawling on
the luminal endothelial surface [17,21,22]. These cells
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EAE or exposed to bacterial products such as LPS and
PTX [17,21]. According to the classical model, the
mechanism underlying this recruitment includes the fol-
lowing steps: 1) proinflammatory cytokines induce the
expression of chemokines and adhesion molecules on
the endothelial surface; 2) these chemokines activate
granulocytes by promoting the conversion of integrins
from a low-affinity to a high-affinity state; and 3) the
latter integrins allow the firm attachment of granulo-
cytes to endothelial adhesion molecules [23]. So far, we
have gathered evidence that PTX induces ICAM1
expression in brain capillaries indirectly through IL-6,
a n dt h a tg r a n u l o c y t e sb i n dt ot h e s ev e s s e l st h r o u g h
interaction between Mac1 (integrin aMb2) and intercel-
lular adhesion molecule 1 (ICAM1) [17]. In contrast,
granulocyte adhesion in response to LPS is independent
of IL-6, but dependent on TNF and IL-1b [17,21]. An
important question that remains to be addressed is what
chemokine(s) control granulocyte adhesion in the cere-
bral microvasculature.
The G-protein-coupled receptor CXCR2 is crucial for
granulocyte infiltration into the brain parenchyma, as
demonstrated using CXCR2-knockout mice exposed to
LPS or Staphylococcus aureus [24,25]. However, it is still
unclear whether CXCR2 intervenes during adhesion
and/or transmigration. CXCR2 binds to chemokines of
the CXC family containing the glutamate-leucine-argi-
nine (ELR) motif (i.e., CXCL1, CXCL2, CXCL3, CXCL5,
and CXCL7 in mouse and human, in addition to
CXCL6 and CXCL8 in human only) [26]. This family
also comprises mouse CXCL15, which does not appear
to bind CXCR2 [27]. Both CXCL1 and CXCL2 are upre-
gulated in the CNS of mice suffering from endotoxemia
[24] or EAE [13,14,16,28-30]. Such information is not
available for the other CXCR2 ligands, leading to ques-
tion the relative importance of these molecules in gran-
ulocyte recruitment into the CNS.
The primary objective of the present study was to
identify the main CXCR2 ligand responsible for granulo-
cyte adhesion to brain capillaries during EAE and after
exposure to bacterial toxins, especially PTX, which is
commonly used as an adjuvant to induce EAE [31], but
whose mechanism of action is still not fully understood.
The second objective was to examine whether the effect
of PTX on CXCL1 expression is mediated by IL-6, a
cytokine essential for EAE development [32-36] and pre-
viously identified as mediating the effect of PTX on
endothelial ICAM1 expression [17].
Methods
Mice
Experiments were performed on male mice aged 8-10
weeks with the approval of our institutional animal
ethics committee. The animals were obtained from
Charles River Laboratories (C57BL/6 mice) or The Jack-
son Laboratory (IL-6-knockout and wild-type mice with
a C57BL/6 background). They were housed individually
in ventilated cages and acclimated for at least 1 week
before use.
Toxin injection
Mice were injected intraperitoneally with 20 μg/kg PTX
(List Biological Laboratories) or 1 mg/kg LPS from
Escherichia coli O55:B5 (Sigma-Aldrich) both diluted in
PBS. Control mice were injected with PBS only.
EAE induction and clinical evaluation
Mice were injected subcutaneously on day 0 with 200 μl
(100 μl/site) of emulsion containing 300 μg of myelin
oligodendrocyte glycoprotein peptide 35-55 (AnaSpec)
dissolved in saline and mixed with an equal volume of
complete Freund’s adjuvant containing 500 μg of killed
Mycobacterium tuberculosis H37 RA (Difco Labora-
tories). The animals were also injected intraperitoneally
with PTX (20 μg/kg) immediately and 48 h after the
first immunization. Clinical signs were monitored daily
and scored as follows: 0, no detectable sign; 0.5, partially
limp tail; 1, paralyzed tail; 2, loss in movement coordi-
nation and hind limb paresis; 2.5, one hind limb paral-
yzed; 3, both hind limbs paralyzed; 3.5, hind limbs
paralyzed and weakness in forelimbs; 4, fore limbs paral-
yzed; 5, moribund or dead [31].
Treatment with neutralizing antibodies
Mice were injected via a tail vein with the following
antibodies (all purchased from R&D Systems) at a con-
c e n t r a t i o no f4o r2 0m g / k gi nP B S :a n t i - C X C L 1( r a t
IgG2A), anti-CXCL2 (rat IgG2B), anti-CXCR2 (rat
IgG2A), and isotype control antibodies (rat IgG2A). A
single injection of these antibodies was given 1 h before
toxin injection, whereas daily injections were given from
day 7 to day 13 after EAE induction.
RNA isolation
T o t a lR N Aw a si s o l a t e df r o mt i s s u e sa n dc u l t u r e dc e l l s
by homogenization in TRI-reagent (Sigma-Aldrich) fol-
lowed by purification using the GenElute Mammalian
Total RNA Miniprep Kit (Sigma-Aldrich). RNA integrity
and quantity were assessed using the Bioanalyzer 2100
capillary electrophoresis system (Agilent Technologies)
and the NanoDrop 2000 spectrophotometer (Thermo
Scientific), respectively.
Quantitative RT-PCR
First strand cDNA was generated from 2 μgo ft o t a l
RNA using Superscript III (Invitrogen) with random
hexamer and 20-mer oligo-dT primers, then purified
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The product (20 ng) was analyzed using the LightCycler
480 system with the SYBR Green I Master mix accord-
ing to the manufacturer’s instructions (Applied Biosys-
tems). The primers were as follows: CXCL1, 5’-
ATCCAGAGCTTGAAGGTGTTG-3’ and 5’-GTCT
GTCTTCTTTCTCCGTTACTT-3’; CXCL2, 5’- ATGCC
TGAAGACCCTGCCAAG-3’ and 5’-GGTCAGTTAG
CCTTGCCTTTG-3’;C X C L 3 ,5 ’-CATCCAGAGCTT-
GACGGTGAC-3’ and 5’-CTTGCCGCTCTTCAG-
TATCTTCTT-3’;C X C L 5 ,5 ’-ACAGTGCCCTACGG
TGGAAGT-3’ and 5’-CGAGTGCATTCCGCTTAGC
TT-3’;C X C L 7 ,5 ’-GGAAAATCTGATGGCATGGAC-3’
and 5’-CAGGCACGTTTTTTGTCCATTCT-3’;S O C S 3 ,
5’-GAGAAGATTCCGCTGGTACTG-3’ and 5’-GCAGC
TGGGTCACTTTCTCATA-3’;I C A M 1 ,5 ’- CCCAAG-
GAGATCACATTCACG-3’ and 5’-TTCCAGGGAG-
CAAAACAACTTCT-3’. The PCR conditions consisted
of 45 cycles of 10 sec at 95°C (denaturation), 10 sec at
60°C (annealing), 12 sec at 72°C (elongation), and 5 sec
at 78°C (reading). The number of cDNA copies was
determined using the second derivative method as
described previously [37].
Immunostaining
Immunohistochemistry was performed as described pre-
viously [21] using the following primary antibodies: rat
anti-CD3 (1:500, Serotec), rat anti-CD31 (1:500, BD
Biosciences), rat anti-CD45 (1:1000, BD Biosciences),
rabbit anti-Iba1 (1:2000, Wako Chemicals), rabbit anti-
GFAP (1:1000, Millipore), and rat anti-Ly6G (1:5000,
BD Biosciences).
In situ hybridization
Brain sections were analyzed by in situ hybridization as
described previously [38]. Combined in situ hybridiza-
tion and immunohistochemistry was performed accord-
ing to a previously described protocol [39].
Stereology
Cells were counted using the optical fractionator meth-
ods as described previously [21].
Flow cytometry
Blood samples were blocked for 15 min with 5 μg/ml
anti-CD16/CD32 antibody (BD Biosciences) and stained
for 30 min on ice with the following antibodies (1 μl
each per 10
6 cells): rat anti-7/4-RPE (Serotec), rat anti-
CD45-FITC (BD Pharmingen), rat anti-CD115-APC
(eBioscience), and rat anti-Ly6G-PerCP-Cy5.5 (BD Phar-
mingen). After hemolysis and fixation with the Whole
Blood Lysing Reagent Kit (Beckman Coulter), cells were
analyzed with a BD FACSCanto II flow cytometer and
FlowJo software (Tree Star).
Cell culture
bEnd.3 cerebral endothelial cells (American Type Cul-
ture Collection) were cultured in six-well plates in
DMEM containing 10% FBS, 100 U/ml penicillin, and
100 μg/ml streptomycin (Sigma-Aldrich). At confluence,
the medium was replaced with fresh medium supple-
mented or not with mouse IL-6 (10 ng/ml, R&D Sys-
tems), mouse IL-6 receptor a (IL-6Ra;1μg/ml, R&D
Systems), and/or rat anti-mouse-IL-6 antibody (40 μg/
ml, R&D Systems). The cells were lysed 3 h later for
RNA isolation. Supernatant was collected for quantifica-
tion of CXCL1 using an ELISA kit (R&D Systems).
Statistical analyses
Data are expressed as mean ± standard error. Means
were compared using the unpaired Student’s t test, one-
way ANOVA, or two-way ANOVA. Alternatively, the
Kruskal-Wallis test was used when the distribution was
abnormal. Student’s t tests or Wilcoxon tests were per-
formed for post hoc multiple comparisons. All these
analyses were performed using JMP (SAS Institute) with
a significance level of 5%.
Results
CXCL1 is the main CXCR2 ligand expressed in the
inflamed CNS
To determine which CXCR2 ligands are expressed in
the brain during inflammatory conditions, we first mea-
sured by quantitative RT-PCR the mRNA levels of these
ligands in the brains of mice killed 6 h after intraperito-
neal injection of PTX (20 μg/kg), LPS (1 mg/kg), or con-
trol solution (PBS). As shown in Figure 1a, both toxins
upregulated CXCL1 and CXCL2 mRNAs by ≥ 80 times
compared to the basal levels. The transcripts of CXCL1
were ~4 times more abundant than those of CXCL2. In
c o n t r a s t ,o n l yL P Su p r e g u l a t e dC X C L 3 ,C X C L 5 ,a n d
C X C L 7m R N A s ,a l b e i tb yn om o r et h a n8t i m e s .T h e s e
transcripts were respectively 108, 7, and 287 times less
abundant than those of CXCL1 in LPS-treated mice.
To confirm the above results and examine the distri-
bution of the cells expressing CXCR2 ligands, we next
analyzed brain sections by in situ hybridization. Many
cells positively labeled for CXCL1 mRNA were detected
throughout the brains of mice exposed to either toxin
(Figure 1b), whereas only a few positive cells were
detected for CXCL2 mRNA (Figure 1b) and none for
CXCL3, CXCL5, or CXCL7 mRNA (data not shown). In
general, the labeled cells appeared to be distributed
along blood vessels, especially those of large caliber. To
confirm this observation, we double labeled brain sec-
tions for CXCL1 mRNA and cell type-specific markers.
The hybridization signals colocalized with the endothe-
lial marker CD31, but not with the microglial marker
Iba1 or the astrocytic marker GFAP (Figure 1c). Similar
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Page 3 of 11Figure 1 Upregulation of CXCR2 ligands in the brain after exposure to bacterial toxins. a, Quantification of the mRNAs encoding each of
the CXCR2 ligands by quantitative RT-PCR using RNA samples prepared from the brains of mice killed 6 h after intraperitoneal injection of PBS,
PTX (20 μg/kg), or LPS (1 mg/kg). The means were compared with the Kruskal-Wallis test (P-values as indicated) followed by post hoc Wilcoxon
tests. For the weakly expressed genes, the means are indicated in parentheses. *Significantly different from the PBS group. Δ = fold change
relative to PBS. n = 5 per group. b, Dark-field micrographs showing in situ hybridization signals for CXCL1 or CXCL2 mRNA in the cerebral cortex
of mice treated with PTX or LPS. No signal was detected in control mice (PBS). Arrows show clusters of emulsion grains indicating the presence
of cells expressing the transcripts. Scale bar = 100 μm. c, Double labeling for CXCL1 mRNA (black grains, in situ hybridization) and different cell
type-specific markers (red-brown, immunohistochemistry) in brain sections from PTX-treated mice. Arrows indicate double-labeled cells.
Arrowheads show examples of immunostained cell bodies negative for CXCL1 mRNA. *Blood vessel lumen. Scale bar = 10 μm.
Roy et al. Journal of Neuroinflammation 2012, 9:18
http://www.jneuroinflammation.com/content/9/1/18
Page 4 of 11observations were made for CXCL2 mRNA (data not
shown).
To examine whether a comparable upregulation of
CXCR2 ligands occurs in EAE, we repeated the experi-
ments described above using RNA and tissue samples
obtained from mice killed from 3 to 12 days after EAE
induction. As observed in LPS-treated mice, all of the
CXCR2 ligands were transcriptionally upregulated in the
brains and spinal cords of EAE mice, the most highly
expressed being CXCL1 (Figure 2a). With a marked
increase noted from day 6, their expression at day 12
was still maximal in the spinal cord, but tended to
decrease in the brain. In contrast to what we observed
with the toxins, the signals detected by in situ hybridiza-
tion were mainly distributed in the choroid plexus and
leptomeninges (Figure 2b), where they colocalized with
CD31 staining and where numerous infiltrating T cells
were present (Figure 2c). Overall, the results presented
thus far indicate that CXCL1 is the main CXCR2 ligand
expressed in the CNS in response to different inflamma-
tory stimuli and originates from the vasculature.
IL-6 induces CXCL1 transcription in endothelial cells
We have previously shown that PTX increases ICAM1
expression in the cerebral endothelium indirectly through
IL-6, which acts post-transcriptionally, but not transcrip-
tionally [17]. To test whether IL-6 also regulates CXCL1
expression, we compared the levels of CXCL1 mRNA in
the brains of IL-6-knockout and wild-type mice injected
with PTX by in situ hybridization. Many strong hybridi-
zation signals were observed in the wild types, but no sig-
nal was detected in the knockouts (Figure 3a). To
complement this experiment, we cultured cerebral
endothelial cells in the presence of IL-6 for 3 h, and
found an increased expression of CXCL1 both at the
mRNA and protein levels (Figure 3b). Although this
effect was not enhanced by the addition of soluble IL-6
receptor, it was totally inhibited by pre-incubation with
an anti-IL-6 antibody, confirming the specificity of the
results. The validity of this experiment is also supported
by the observations that SOCS3 and ICAM1 mRNAs
were respectively upregulated and unaffected by IL-6, as
expected from previous studies [17,40]. Altogether, these
findings demonstrate that IL-6 can regulate CXCL1
expression by acting at the transcriptional level.
CXCL1 promotes granulocyte adhesion to cerebral blood
vessels
We have previously reported that the population of
adherent intraluminal leukocytes (CD45
high cells with a
round or rod-shape morphology) increases in the cere-
bral vasculature after exposure to bacterial toxins, and
that this response is largely attributable to de novo
recruitment of granulocytes [17]. To examine the
importance of CXCL1 in this response, we pretreated
mice with 4 mg/kg anti-CXCL1, anti-CXCR2 (positive
control), or isotype antibody (negative control) before
challenging them with PTX or LPS. Histological analysis
revealed that the increase in rod-shaped leukocytes in the
vasculature of the cerebral cortex was reduced by ~69%
by the anti-CXCL1 and anti-CXCR2 antibodies in mice
exposed to PTX, but was reduced to a similar extent only
by the anti-CXCR2 antibody in mice exposed to LPS
(Figure 4a, b). In contrast, the number of round leuko-
cytes was not affected by any treatment. To verify
whether the lack of effect of the anti-CXCL1 antibody in
LPS-treated mice was due to a compensatory effect of
CXCL2 or the use of a suboptimal dose of anti-CXCL1
antibody, we repeated the analysis with LPS-challenged
mice pre-treated with either a combination of anti-
CXCL1 and anti-CXCL2 antibodies (both at 4 mg/kg) or
a higher dose of anti-CXCL1 antibody (20 mg/kg). We
observed a reduction in the recruitment of rod-shape leu-
kocytes only with the latter treatment (Figure 4c), sug-
gesting that LPS induces a higher increase in CXCL1
than PTX and that a higher dose of anti-CXCL1 antibody
is required for effective pharmacological blockade. This is
supported by the observation that increased serum levels
of CXCL1 were detected by ELISA in LPS-treated mice,
but not in PTX-treated mice (LPS, 1.3 ng/ml; PTX, 0.40
ng/ml; PBS, 0.33 ng/ml; ANOVA, P = 0.019). Finally, to
exclude a possible effect of the antibodies on the circulat-
ing pool of granulocytes, we analyzed blood samples col-
lected at the time of sacrifice by flow cytometry. No
significant difference in the number of CD45
+7/4
+Ly6G
+CD115
- cells was found among the animals that received
the different antibodies (data not shown; ANOVA, P =
0.5), suggesting that the anti-CXCL1 and anti-CXCR2
antibodies blocked the adhesion of granulocytes, but not
their mobilization or survival.
To assess whether CXCL1 contributes to EAE devel-
opment by promoting granulocyte recruitment, we
injected mice once daily with 4 mg/kg anti-CXCL1 anti-
body from day 7 to day 13 after EAE induction by active
immunization. Blind evaluation of the clinical symptoms
revealed a reduction in EAE severity in these mice com-
pared to sham-treated animals (Figure 5a). All the mice
were killed 4 h after the last injection to collect their
brains for histological analyses. Because the populations
of intravascular rod-shaped leukocytes found in the
brains of EAE mice comprises not only granulocytes but
also T lymphocytes [17], we distinguished these cells by
using antibodies against the granulocyte marker Ly6G
and the T cell marker CD3 (Figure 5b). Stereological
cell counts showed a 38% reduction in the number of
Ly6G
+ rod-shaped cells, but no significant change
regarding the subpopulation of CD3
+ rod-shaped cells
(Figure 5c) or the total population of CD3
+ cells (isotype
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Page 5 of 11Figure 2 Upregulation of CXCR2 ligands in the brain and spinal cord during EAE. a, Quantification of the mRNAs encoding each of the
CXCR2 ligands by quantitative RT-PCR using RNA samples prepared from the brains or spinal cords of mice killed at the indicated time intervals
after EAE induction (as shown in Additional file 1: Figure S1, the first clinical symptoms were observed on day 8). The means were compared
with the Kruskal-Wallis test (P-values as indicated) followed by post hoc Wilcoxon tests. *Significantly different from day 3. Δ = fold change
relative to day 3. n = 6 (days 3, 6, and 10), 5 (day 8), or 3 (day 12). b, Dark-field and bright-field micrographs showing in situ hybridization signals
for CXCL1, CXCL2, or CXCL5 mRNA in the leptomeninges of EAE mice killed 6 days after EAE induction. Arrows show clusters of emulsion grains
indicating the presence of cells expressing the transcripts. Scale bar = 50 μm. c, Double labeling for CXCL1 mRNA (black grains, in situ
hybridization) and different cell type-specific markers (red-brown, immunohistochemistry) in brain sections from EAE mice. These images were
taken at the level of the leptomeninges. Arrows indicate double-labeled cells. Arrowheads show examples of immunostained cell bodies
negative for CXCL1 mRNA. Scale bar = 10 μm.
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3; anti-CXCL1 antibody, 971 ±
193/mm
3). Also reduced was the population of Ly6G
+
rounded granulocytes (Figure 5c), which was > 4 times
greater than that found in mice treated with bacterial
toxins and included not only intraluminal, but also
intraparenchymal cells (Figure 5d). Overall, this last ser-
ies of experiments demonstrates that CXCL1 plays an
important role in different neuroinflammatory condi-
tions by promoting granulocyte adhesion to the cerebral
microvasculature.
Discussion
As growing evidence suggests that granulocytes contri-
bute to EAE and perhaps multiple sclerosis, there is
high interest in understanding how these cells are
recruited in the CNS. While the cytokines and adhesion
molecules involved in this recruitment have started to
be identified (e.g., IL-6, IL-1b,T N F ,I C A M 1 ,M a c 1 )
[17,21], the required chemokine was undetermined prior
to the present study. Our results reveal that CXCL1 is a
major CXCR2 ligand upregulated in cerebral endothelial
cells at least by IL-6 in different inflammatory condi-
tions. They also show that CXCL1 plays an essential,
non-redundant role in the recruitment of granulocytes
by promoting their adhesion to capillaries. Finally, and
as discussed below, our results not only help to under-
stand the mechanism of action of PTX and the impor-
tance of granulocytes in EAE, but provide a pre-clinical
validation for the use of CXCL1 inhibitors for the treat-
ment of neuroinflammatory disorders.
Mechanism of action of PTX
To induce EAE, the most studied animal model of mul-
tiple sclerosis, mice immunized with myelin antigens or
transplanted with myelin-reactive T cells are commonly
Figure 3 Regulation of CXCL1 expression by IL-6 in cerebral
endothelial cells in vivo and in vitro. a, Dark-field micrographs of
brain sections collected from IL-6 knockout and wild-type mice
killed 6 h after intraperitoneal injection of PTX (20 μg/kg) and
analyzed for CXCL1 mRNA by in situ hybridization. Positively labeled
cells (arrows) are seen only in the wild-type mouse (representative
of 6 mice per genotype). Scale bar = 50 μm. b, Quantification of
CXCL1 expression by quantitative RT-PCR or ELISA in cultures of
bEnd.3 cerebral endothelial cells exposed for 3 h to IL-6 (10 ng/ml),
soluble IL-6 receptor (IL-6Ra,1μg/ml), and/or neutralizing anti-IL-6
antibody (40 μg/ml). SOCS3 and ICAM1 mRNAs were used as a
positive or negative control, respectively. The PCR data were
compared with the Kruskal-Wallis test (P-values as indicated)
followed by post hoc Wilcoxon tests. The ELISA data were compared
using ANOVA (P-value as indicated) followed by post hoc Student’s t
tests. *Significantly different from the control group. n = 6 per
condition.
Figure 4 Contribution of the CXCL1-CXCR2 axis to leukocyte
adhesion within the cerebral vasculature in response to
bacterial toxins. a, Micrographs of intravascular leukocytes (arrows)
with a rod-shaped or rounded morphology in mouse brain sections
stained for CD45 by immunohistochemistry. Arrowheads =
microglial processes. Scale bar = 5 μm. b, Counts of CD45
+
intravascular leukocytes (rod-shaped and round) in the cerebral
cortex of mice treated with anti-CXCL1, anti-CXCR2, or isotype
antibody (4 mg/kg), and killed 6 h after intraperitoneal injection of
PBS, PTX (20 μg/kg), or LPS (1 mg/kg). The means were compared
using ANOVA (P-values as indicated) followed by post hoc Student’s
t tests. *Significantly different from the corresponding isotype
group. n = 6-10 per group. c, Data from an experiment similar to
the one shown in b, except that LPS-challenged mice received a
higher dose of anti-CXCL1 antibody (20 mg/kg instead of 4 mg/kg)
or a combination of anti-CXCL1 and anti-CXCL2 antibodies (4 mg/
kg each). n = 7 per group.
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the bacteria causing whooping cough and used as an
adjuvant to increase EAE incidence and severity [31,41].
The mechanism by which PTX promotes EAE is still
not fully understood and seems paradoxical considering
its ability to block leukocyte migration by interfering
with G protein-coupled receptor signaling [42]. We have
recently published evidence that PTX increases endothe-
lial adhesiveness indirectly through circulating mediators
such as IL-6 [17]. The latter induces ICAM1 expression
in brain capillaries by acting post-transcriptionally, lead-
ing to the recruitment of leukocytes capable of patrol-
ling the cerebrospinal vasculature by crawling on its
luminal surface. As illustrated in Figure 6, the present
study extends this concept by demonstrating that IL-6 is
also responsible for the upregulation of a chemokine
that promotes granulocyte adhesion and EAE develop-
ment, this time by acting transcriptionally. To complete
our model, it will now be interesting to identify the che-
moattractant that informs granulocytes on where to
penetrate the CNS parenchyma, as well as to delineate
the mechanism sensing PTX and initiating this entire
inflammatory cascade.
Importance of granulocytes and the CXCL1-CXCR2 axis in
EAE
Although a beneficial role of CXCL1 and granulocytes
may be drawn from a study showing that forced overex-
pression of CXCL1 in astrocytes decreases the severity
of EAE [43], many studies in which CXCR2 was neutra-
lized or granulocytes were depleted actually suggest the
opposite [12,18-20]. In agreement with the latter studies,
we show here that the number of adherent granulocytes
and the severity of EAE were reduced in mice treated
with an anti-CXCL1 antibody during the effector phase
of the disease, suggesting that CXCL1 significantly
Figure 5 Contribution of CXCL1 to the development of EAE. a, Clinical scores of EAE mice injected intravenously once daily from day 7 with
4 mg/kg anti-CXCL1 antibody or isotypic control antibody. The means were compared by multivariate ANOVA with repeated measures (P-value
as indicated) followed by post hoc Student’s t tests. *Significantly different from the isotype group. n = 9-11 per group. b, Micrographs of
different subsets of leukocytes stained for Ly6G or CD3 by immunohistochemistry in brain sections from mice killed 13 days after EAE induction.
Scale bar = 5 μm. c, Counts of leukocytes in the cerebral cortex of EAE mice treated or not with anti-CXCL1 antibody and killed at day 13. The
means were compared using the Student’s t test. *Significantly different from the isotype group. n = 9-11 per group. d, Micrographs of
granulocytes located inside (arrows) or outside (arrowheads) brain capillaries in a EAE mouse. Black = Ly6G immunoperoxidase staining using
nickel-DAB as a substrate. Red-brown = CD31 immunoperoxidase staining using DAB as a substrate. Scale bar = 10 μm.
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Page 8 of 11contributes to EAE by promoting granulocyte recruit-
ment. As recently reviewed [44], granulocytes may play
different roles in EAE, such as the secretion of immu-
noregulatory molecules that would sustain the activity/
recruitment of other immune cells and the execution of
effector functions that would damage the myelin sheath.
It will be important in future work to test these possibi-
lities, but this will require the development of new gran-
ulocyte-specific genetic mouse models.
CXCL1 as a potential therapeutic target
Genetic deletion or pharmacological blockade of CXCR2
has been shown to inhibit EAE [12,19,20]. Considering
that CXCR2 can bind to several ligands, one can predict
that blocking this receptor would be less specific and
more immunocompromising than blocking CXCL1. It
may thus be advantageous to develop CXCL1 inhibitors
that would allow the action of the other CXCR2 ligands,
which might be significantly produced under various
conditions. The present study supports the latter
approach by showing that an anti-CXCL1 antibody can
improve the clinical symptoms of EAE, although the
improvement we observed was lower than that obtained
in other laboratories by targeting CXCR2 [12,19]. Differ-
ent reasons might explain the lower effectiveness of our
anti-CXCL1 treatment, such as the use of a non-optimal
dose or frequency of injection, and a loss of activity
over time due to the establishment of an anti-drug
immune response. Developmental research should be
considered to optimize the therapeutic use of anti-
CXCL1 antibodies and to determine whether other anti-
CXCL1 inhibitors could be advantageous. Furthermore,
the importance of examining whether blocking CXCL1
would be safe in the long term and efficient in all types
of EAE and multiple sclerosis is underscored by the
observations that CXCL1 influences the biology of mye-
linating cells [45-48] and that both CXCL1 expression
and neutrophil infiltration are higher during Th17 cell-
mediated EAE compared to Th1 cell-mediated EAE
[12,13].
Conclusions
This study highlights the importance of the CXCL1-
CXCR2 axis in the recruitment of granulocytes at the
blood-brain interface and in the development of EAE.
The challenges are now to determine whether other
CXCR2 ligands exert a significant influence on these
processes despite lower expression levels, to elucidate
the precise functions of granulocytes in demyelinating
diseases, and to translate this knowledge into new thera-
peutic strategies for multiple sclerosis.
Additional material
Additional file 1: Figure S1. Mean clinical scores of EAE mice used in
the experiment shown in Figure 1 on the day of sacrifice. n=6 (days 3,
6, and 10), 5 (day 8), or 3 (day 12).
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